Multiple sclerosis drug pipeline

Mar 03, 2020

Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease

Mar 29, 2019

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

Mar 29, 2019

FDA approves new oral treatment for multiple sclerosis

Mar 26, 2019

FDA approves new oral drug to treat multiple sclerosis

Oct 08, 2018

Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients

Jul 30, 2018

FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis

Feb 06, 2018

British Columbia includes (Pr)LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients

Dec 04, 2017

Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada

Nov 09, 2017

NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis

Oct 28, 2017

Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Oct 18, 2017

Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017

May 30, 2017

Bayer Receives FDA Approval of myBETAapp(TM) and BETACONNECT Navigator(TM)